By integrating molecular mechanisms with emerging clinical relevance, we highlight current challenges and the potential of targeting CD147-centered glycoprotein networks to disrupt niche formation, thus further improving clinical outcomes for advanced cancer patients. This evidence concerns the gene BSG and cancer.